BARC Developed Eye Cancer Therapy

 The Bhabha Atomic Research Center (BARC) in Mumbai has developed the first indigenous Ruthenium 106 Plaque form of eye cancer therapy to treat Ocular Tumours. This is expected to reduce the cost of treatment of ocular tumors in the country. It is said that the newly developed plaque complies with international standards.

Ocular Tumors:

Ocular tumors are tumors inside the eye. They are collections of cells that grow and multiply abnormally and form masses. Radiotherapy and chemotherapy are two common treatments for ocular tumors. The radiation can be in the form of proton beam radiation or placement radiation plaques on the eyes.

Ruthenium 106 (Ru-106) plaque brachytherapy:

Ruthenium 106 (Ru-106) plaque brachytherapy is used to treat many types of tumors. Brachytherapy is a procedure in which radioactive materials are placed inside the body. This is a type of radiation therapy used for cancer treatment. It is also called internal radiation. It allows doctors to provide higher doses of radiation to specific parts of the body.

BARC:

Bhabha Atomic Research Center (BARC) is India’s main nuclear research institution, established in 1954. It is Headquartered in Mumbai, and it is a multi-disciplinary research center with extensive infrastructure for advanced research and development, covering the entire nuclear science, engineering, and related fields. It comes under the Department of Atomic Energy. BARC operates a number of research reactors across the country.